Zacks Investment Research upgraded shares of Invuity, Inc. (NASDAQ:IVTY) from a sell rating to a hold rating in a report published on Wednesday, October 4th.

According to Zacks, “Invuity, Inc. is a medical technology company. Its products include Eikon Illuminated Retractor System, Saber Yankauer, Saber Frazier, Eika Illuminated Retractor System, Breiten Illuminated Retractor System, Eipex Illuminated Retractor System, Eivector Illuminated Retractor System and Waveguide XT System. The Company sells its devices through its direct sales representatives and original equipment manufacturers of surgical systems. Invuity, Inc. is based in San Francisco, California. “

Other analysts also recently issued reports about the company. Piper Jaffray Companies reaffirmed a buy rating and issued a $10.00 target price on shares of Invuity in a research note on Wednesday, July 26th. Northland Securities set a $13.00 price objective on Invuity and gave the stock a buy rating in a research report on Tuesday, June 13th. Finally, ValuEngine raised Invuity from a strong sell rating to a sell rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. Invuity has an average rating of Buy and an average price target of $11.00.

Invuity (NASDAQ:IVTY) traded down 1.68% during mid-day trading on Wednesday, hitting $8.80. 31,477 shares of the stock traded hands. Invuity has a 1-year low of $4.50 and a 1-year high of $12.25. The company’s 50 day moving average price is $8.67 and its 200-day moving average price is $8.67. The stock’s market cap is $150.04 million.

Invuity (NASDAQ:IVTY) last issued its earnings results on Tuesday, July 25th. The medical instruments supplier reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.07). Invuity had a negative return on equity of 140.69% and a negative net margin of 114.61%. The company had revenue of $9.77 million during the quarter, compared to analyst estimates of $10.30 million. Analysts predict that Invuity will post ($2.38) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was originally published by Marea Informative and is owned by of Marea Informative. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at http://www.mareainformativa.com/invuity-inc-ivty-upgraded-by-zacks-investment-research-to-hold/118030/.

A number of institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can purchased a new position in shares of Invuity in the 1st quarter valued at about $112,000. FMR LLC boosted its stake in shares of Invuity by 0.5% in the 1st quarter. FMR LLC now owns 829,564 shares of the medical instruments supplier’s stock valued at $6,595,000 after buying an additional 4,264 shares during the period. Royce & Associates LP boosted its stake in shares of Invuity by 84.4% in the 1st quarter. Royce & Associates LP now owns 40,906 shares of the medical instruments supplier’s stock valued at $325,000 after buying an additional 18,726 shares during the period. UBS Group AG boosted its stake in shares of Invuity by 53.4% in the 1st quarter. UBS Group AG now owns 13,200 shares of the medical instruments supplier’s stock valued at $105,000 after buying an additional 4,594 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of Invuity in the 1st quarter valued at about $151,000. Institutional investors own 68.87% of the company’s stock.

About Invuity

Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.

Get a free copy of the Zacks research report on Invuity (IVTY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Invuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity Inc. and related stocks with our FREE daily email newsletter.